期刊文献+

尼可地尔联合水化对伴有肾功能不全的冠心病患者造影剂肾病的预防作用 被引量:7

Preventive Effect of Nicorandil Combined with Hydration on Contrast-Induced Nephropathy in Patients with Coronary Heart Disease with Renal Insufficiency
下载PDF
导出
摘要 目的探讨尼可地尔联合水化对伴有肾功能不全的冠心病患者造影剂肾病的预防作用。方法选取于河南大学第一附属医院2017年10月至2019年7月行择期冠状动脉造影术或冠状动脉支架植入术的肾功能不全的冠心病患者,将入组患者按照治疗方法分为尼可地尔联合水化组(63例)和单纯水化组(66例)。比较两组术后48 h造影剂肾病的发生率,测定两组术前和术后48 h血肌酐、胱抑素C、肾小球滤过率(eGFR)水平。结果尼可地尔联合水化组造影剂肾病的发生率(9.50%)低于单纯水化组(22.73%),差异有统计学意义(P<0.05)。尼可地尔联合水化组术后48 h肌酐及胱抑素C水平低于单纯水化组,eGFR水平高于单纯水化组,差异有统计学意义(均P<0.05)。结论尼可地尔联合水化可降低伴有肾功能不全的冠心病患者造影剂肾病的发生率。 Objective To investigate the preventive effect of nicorandil combined with hydration on contrast-induced nephropathy in patients with coronary heart disease with renal insufficiency.Methods Patients with coronary artery disease with renal insufficiency performed in selective coronary angiography or coronary stent implantation in the First Affiliated Hospital of Henan University from October 2017 to July 2019 were divided into nicorandil combined hydration group(63 cases) and simple hydration group(66 cases) according to the treatment. The incidence of postoperative 48-hour contrast-induced nephropathy in the two groups was compared, and preoperative and postoperative 48-hour levels of serum creatinine, cystatin C, and glomerular filtration rate(eGFR) were measured in the two groups.Results The incidence of contrast-induced nephropathy in nicorandil combined hydration group(9.50%) was lower than that in simple hydration group(22.73%), and the difference was statistically significant(P<0.05). The levels of creatinine and cystatin C in nicorandil combined hydration group were lower than those in simple hydration group 48-hour after operation, and the level of eGFR was higher than that in simple hydration group(all P<0.05).Conclusion Nicorandil combined with hydration could reduce the incidence of contrast-induced nephropathy in patients with coronary heart disease with renal insufficiency.
作者 马光 王国良 李敏 侯德和 肖东斌 薛永亮 滕伟 MA Guang;WANG Guo-liang;LI Min;HOU De-he;XIAO Dong-bin;XUE Yong-liang;TENG Wei(Department of Cardiovascular,the First Affiliated Hospital of Henan University,Kaifeng 475001,China)
出处 《河南医学研究》 CAS 2020年第16期2890-2892,共3页 Henan Medical Research
基金 开封市社会发展科技攻关计划(1803011)。
关键词 造影剂肾病 尼可地尔 肾功能不全 冠心病 contrast-induced nephropathy nicorandil renal dysfunction coronary heart disease
  • 相关文献

参考文献1

二级参考文献31

  • 1Lekston A, Kurek A, Tynior B. Impaired renal function in acute myocardial infarction. Cardiol J 2009;16:400-406.
  • 2Leveridge M J, Bostrom P J, Koulouris G, Finelli A, Lawrentschuk N. Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nature Rev Urol 2010;7:311-325.
  • 3Ari E, YiLmaz Y, Kedrah AE, Alahdab Y, Cakalagaoglu F, Arikan H, et al. Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy. Am J Nephrol 2011 ;33:269-276.
  • 4Bell RM, Rear R, Cunningham J, Dawnay A, Yellon DM. Effect of remote ischemic conditioning on contrast-induced nephropathy in patients undergoing elective coronary angiography (ERICCIN): rationale and study design of a randomised single-centre, double-blind placebo-controlled trial. Clin Res Cardiol 2014;103:203-209.
  • 5Pflueger A, Abramowitz D, Calvin AD. Role of oxidative stress in contrast-induced acute kidney injury in diabetes mellitus. Med Sci Monit 2009;15:RA125-RA136.
  • 6Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Intern 2005;68:14-22.
  • 7Wong PCY, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. Intern J Cardiol 2012;158:186-192.
  • 8Wu M, Hsiang H, Wong C, Yao M, Li Y, Hsiang C. et al. The effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta- analysis of randomized controlled trials. Intern Urol Nephrol 2013;45:1309-1318.
  • 9Sun ZK, Fu Q, Cao LX, Jin W, Cheng LL, Li Z. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PIoS One 2013;8:e55124.
  • 10Brown R, Gerbarg P, Ramazanov Z. Rhodiola rosea; a phytomedicinal overview. Herbal Gram 2002:56:40-52.

共引文献8

同被引文献52

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部